Lyell Immunopharma (NASDAQ:LYEL) Now Covered by Analysts at Citizens Jmp

Research analysts at Citizens Jmp assumed coverage on shares of Lyell Immunopharma (NASDAQ:LYEL) in a report issued on Monday,Benzinga reports. The brokerage set a “market outperform” rating and a $34.00 price target on the stock. Citizens Jmp’s price objective would suggest a potential upside of 51.38% from the company’s current price.

LYEL has been the subject of several other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Thursday, January 22nd. HC Wainwright raised Lyell Immunopharma from a “neutral” rating to a “buy” rating and raised their target price for the company from $20.00 to $45.00 in a report on Tuesday, December 9th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Lyell Immunopharma presently has a consensus rating of “Hold” and an average target price of $39.50.

Lyell Immunopharma Stock Up 1.9%

Shares of LYEL stock opened at $22.46 on Monday. The company has a market cap of $477.05 million, a PE ratio of -0.98 and a beta of -0.14. The business’s 50 day moving average is $24.85 and its two-hundred day moving average is $21.14. Lyell Immunopharma has a 12 month low of $7.65 and a 12 month high of $45.00.

Insider Transactions at Lyell Immunopharma

In other news, COO Stephen J. Hill sold 1,236 shares of the business’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total transaction of $28,910.04. Following the transaction, the chief operating officer owned 17,795 shares in the company, valued at approximately $416,225.05. The trade was a 6.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Lynn Seely sold 7,455 shares of the company’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total transaction of $174,372.45. Following the transaction, the chief executive officer directly owned 74,266 shares of the company’s stock, valued at $1,737,081.74. This represents a 9.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 11,310 shares of company stock worth $264,285. 22.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Lyell Immunopharma

Large investors have recently added to or reduced their stakes in the company. Clarius Group LLC grew its holdings in shares of Lyell Immunopharma by 4.3% during the 3rd quarter. Clarius Group LLC now owns 19,958 shares of the company’s stock worth $324,000 after purchasing an additional 820 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Lyell Immunopharma by 7.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 85,423 shares of the company’s stock valued at $2,629,000 after purchasing an additional 5,913 shares in the last quarter. BBR Partners LLC bought a new position in Lyell Immunopharma in the fourth quarter worth $210,000. ExodusPoint Capital Management LP acquired a new stake in Lyell Immunopharma during the fourth quarter worth $262,000. Finally, Marshall Wace LLP acquired a new stake in Lyell Immunopharma during the second quarter worth $94,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.